Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Scientists Find Gene that Causes Drug Resistance in Cancer

Published: Wednesday, January 16, 2013
Last Updated: Wednesday, January 16, 2013
Bookmark and Share
The discovery is a first step in creating new, effective therapeutic treatments for sufferers of aggressive cancers.

“There are not a lot of options for cancer patients with diseases such as myeloma,” said BYU biology professor David Bearss, a coauthor on the study published Jan. 14 in the journal Cancer Cell. “Myeloma is not only an extremely painful cancer, but it is also a disease that is resistant to treatment.”

Multiple myeloma is a cancer of plasma cells that exists exclusively in the bone. Over time the cancer cells take over bone marrow and destroy its function. This results in major health problems, including failure of the immune system, loss of kidney function, a drop in red blood cell count and large soft spots or holes that form in bones. These holes lead to painful fractures throughout the body, from the skull to hips to the spine.

Compounding that pain for patients is that myeloma cells quickly become resistant to chemotherapy and other drugs, resulting in a short life expectancy for those diagnosed. Over the last few years lead researchers Fenghuang (Frank) Zhan and Guido Tricot, along with Bearss, have been trying to figure out how the disease develops drug resistance.

For the Cancer Cell study, the team carried out a genomic analysis of the biopsied cells of 19 myeloma patients, taken from different stages of their cancer development. They wanted to see what was happening on the genetic level as the disease progressed.

They found that patients with the most aggressive forms of myeloma, and the patients with the poorest drug response, were those who had a high expression of the gene NEK2. That finding led the team to start going after the gene in the lab to see what would happen.

“Silencing NEK2 in cancer cells potently decreased drug resistance, induced cell-cycle arrest, cell death, and inhibition of cancer cell growth in vitro and in vivo," said Zhan, professor of internal medicine at University of Iowa’s Carver College of Medicine.

Added Bearss: “We were able to show that if we inhibit NEK2, then we can actually restore sensitivity to drugs that we use right now.”

The research results also indicate that NEK2 can be used in diagnostic testing.

“We’ve found that this gene is not just a predictor of poor therapy response in myeloma, but is a predictor to poor response in other cancers, such as breast cancer, lung cancer and other major tumor types,” Bearss said. “A big take home from this study is that we could potentially use NEK2 for early screening of patients so we could treat patients with higher levels more aggressively.”

Bearss and his BYU undergraduate student team are now working toward the development of drugs that specifically target NEK2. Their hope is to develop a compound that is minimally toxic to normal cells while having a high selectivity to cancer cells.

The Iowa-BYU research team is currently in the third year of a five-year National Institute of Health grant. The goal is to be ready to take newly formed compounds into human studies by the end of the grant period.

"This study shows convincingly that genomic changes over time are culprit in more aggressive cancer behavior,” said Dr. Rafael Fonseca, Chair of the Department of Medicine at Mayo Clinic in Arizona, who was not involved in the study. “It is likely that for cancers the major risk factors for poor prognosis are not the specific cancer genetic changes, but rather the ability of any given cancer to change, mutate and evolve."

A good portion of Professor Bearss’ contribution to this research study occurred while he was Co-Director of the Center for Investigational Therapeutics and an associate professor of oncology at the University of Utah’s Huntsman Institute of Cancer. Collaborators Zhan and Tricot were also both formerly at the Huntsman Cancer Institute.

Dr. Tricot currently serves as the director of Holden Comprehensive Cancer Center’s Bone Marrow Transplant and Myeloma Program at University of Iowa Hospitals and Clinics.

Bearss joined BYU’s Department of Physiology and Developmental Biology in the fall of 2012, after three years as a professor at the Huntsman Cancer Institute.

Dr. Bearss also served on the faculty of the University of Arizona and has founded and led numerous pharmaceutical startup companies during his career.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Developing Novel Ear Infection Treatments
Research team engineers antibiotic gel for treating middle ear infections.
Wearable Microscope Can Measure Fluorescent Dyes Through Skin
UCLA research could make monitoring disease biomarkers easier and more cost-effective.
Potential of New Insect Control Traits in Agriculture
Researchers have discovered a protein that shows promise as an alternate corn rootworm control mechanism.
Fighting Cancer with Sticky Nanoparticles
Treatment that uses bioadhesive nanoparticles drug carriers proved more effective than conventional treatments for certain cancers.
Fighting Plant Pathogens with RNA
Researchers develop strategy that could lead to environmentally friendly fungicide to fight pathogens.
Smart Material Hunts Cancers
Team has created smart material that locates and images cancer or tumour sites in tissue.
Examining mtDNA May Help Identify Unknown Ancestry That Influences Breast Cancer Risk
Researchers studying mtDNA in a group of triple negative breast cancer patients found that 13 percent of participants were unaware of ancestry that could influence their risk of cancer.
Gene Therapy Technique May Help Prevent Cancer Metastasis
Gene-regulating RNA molecules could help treat early-stage breast cancer tumors before they spread.
Enhancing Antibiotics to Defeat Resistant Bacteria
Scientists enhance ability of antibiotics to defeat resistant types of bacteria using molecules called PPMOs
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!